drugset / Trial / NCT03542773
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
Phase 1
Completed
38 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.
Timeline
- Start
- 2015-02-06
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 331 mbq | Intravenous |